

Acetylsalicylic acid



Essential medicine status ✓

Section: 29. Medicines for diseases of joints > 29.3. Medicines for juvenile joint diseases

EMLc

ATC codes: N02BA01

| | |
|--------------------------|---|
| Indication | Mucocutaneous lymph node syndrome ICD11 code: 4A44.5 |
| Medicine type | Chemical agent |
| List type | Complementary (EML) (EMLc) |
| Additional notes | Acute or chronic use for rheumatic fever, juvenile arthritis , Kawasaki disease |
| Formulations | Oral > Solid: 100 to 500 mg Local > Rectal > Suppository: 50 to 150 mg |
| EML status history | First added in 2007 (TRS 950) Changed in 2013 (TRS 985) |
| Sex | All |
| Age | Also recommended for children |
| Therapeutic alternatives | The recommendation is for this specific medicine |
| Patent information | Patents have expired in most jurisdictions Read more about patents . |
| Wikipedia | Acetylsalicylic acid |
| DrugBank | Acetylsalicylic acid |

Summary of evidence and Expert Committee recommendations

A new section of the Model Lists for “Medicines for diseases of joints” was created to list the treatments for gout and the disease-modifying agents used in rheumatoid disorders and juvenile joint diseases that were previously included in Section 2. Thus, acetylsalicylic acid for the treatment of Kawasaki disease in children was transferred to this new section.

